Clinical trial
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class…
NCT00232180 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00232180 |
|---|---|
| Title | A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines |
| Official title | The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure |
| Acronym | EMPHASIS-HF |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Drug |
| Interventions | Eplerenone |
| Enrollment | 2,743 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | Jan 1, 2012 |
| First posted | Oct 4, 2005 |
| Last update posted | Dec 22, 2020 |
| Countries | Argentina, Australia, Belgium, Canada, Czechia, France, Germany, Greece, Hong Kong, Hungary, India, Ireland and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: